NCT Number
stringlengths 11
11
| Study Title
stringlengths 18
300
| Study URL
stringlengths 44
44
| Study Status
stringclasses 13
values | Conditions
stringlengths 3
11.1k
⌀ | Interventions
stringlengths 5
1.2k
⌀ | Sponsor
stringlengths 3
121
| Collaborators
stringlengths 2
3.21k
⌀ | Study Type
stringclasses 3
values |
|---|---|---|---|---|---|---|---|---|
NCT01252277
|
Breast Cancer Risk Biomarkers in Premenopausal Women
|
https://clinicaltrials.gov/study/NCT01252277
|
COMPLETED
|
Breast Cancer
|
DRUG: Lovaza™
|
Carol Fabian, MD
| null |
INTERVENTIONAL
|
NCT00390377
|
Use of Hair to Diagnose Breast Cancer
|
https://clinicaltrials.gov/study/NCT00390377
|
UNKNOWN
|
Breast Cancer
|
PROCEDURE: Cutting scalp hair
|
Fermiscan Ltd
| null |
INTERVENTIONAL
|
NCT01088477
|
Imaging of ER Density to Guide and Improve Tailored Therapy for Acquired Anti-hormonal Resistant Breast Cancer
|
https://clinicaltrials.gov/study/NCT01088477
|
COMPLETED
|
Breast Cancer
|
OTHER: Diagnostic intervention: Positron Emission Tomography with 16-alpha-[18-fluoro]-17betaestradiol
|
University Medical Center Groningen
|
Dutch Cancer Society
|
OBSERVATIONAL
|
NCT00793377
|
Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-Doc) Versus Dose-Dense Doxorubicin and Docetaxel (ADoc) in Breast Cancer
|
https://clinicaltrials.gov/study/NCT00793377
|
COMPLETED
|
Primary Breast Cancer
|
DRUG: Adriamycin (Doxorubicin), Docetaxel, Tamoxifen|DRUG: Adriamycin (Doxorubicin), Docetaxel, Tamoxifen, Cyclophosphamid
|
German Breast Group
|
German Adjuvant Breast Cancer Group
|
INTERVENTIONAL
|
NCT04461977
|
Acupuncture for Peripheral Neuropathy Induced by Paclitaxel in Early Stage Breast Cancer
|
https://clinicaltrials.gov/study/NCT04461977
|
UNKNOWN
|
Peripheral Neuropathy Due to Chemotherapy
|
OTHER: True acupuncture|OTHER: Sham acupuncture
|
Instituto Brasileiro de Controle do Cancer
| null |
INTERVENTIONAL
|
NCT06188494
|
UNFOLD Study Egypt
|
https://clinicaltrials.gov/study/NCT06188494
|
NOT_YET_RECRUITING
|
Breast Cancer
| null |
AstraZeneca
| null |
OBSERVATIONAL
|
NCT05422794
|
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
|
https://clinicaltrials.gov/study/NCT05422794
|
RECRUITING
|
Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Locally Advanced Triple-Negative Breast Carcinoma|Metastatic Triple-Negative Breast Carcinoma|Unresectable Triple-Negative Breast Carcinoma
|
DRUG: BET Bromodomain Inhibitor ZEN-3694|PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|PROCEDURE: Magnetic Resonance Imaging|DRUG: Nab-paclitaxel|BIOLOGICAL: Pembrolizumab
|
National Cancer Institute (NCI)
| null |
INTERVENTIONAL
|
NCT05122494
|
A Phase Ⅲ Study of the Efficacy and Safety of Hemay022+Aromatase Inhibitor(AI) in Participants With ER+/HER2+ Advanced or Metastatic Breast Cancer
|
https://clinicaltrials.gov/study/NCT05122494
|
RECRUITING
|
Breast Cancer
|
DRUG: Hemay022+AI|DRUG: Lapatinib+Capecitabine
|
Tianjin Hemay Oncology Pharmaceutical Co., Ltd
| null |
INTERVENTIONAL
|
NCT05000294
|
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
|
https://clinicaltrials.gov/study/NCT05000294
|
SUSPENDED
|
Bile Duct Cancer|Gall Bladder Cancer|Breast Cancer|Neuroendocrine Tumors|Ovarian Cancer|Pancreatic Adenocarcinoma|Soft Tissue Sarcoma|Vulvar Cancer|Prostate Cancer
|
DRUG: Atezolizumab|DRUG: Tivozanib
|
University of Florida
|
Genentech, Inc.|Aveo Oncology Pharmaceuticals
|
INTERVENTIONAL
|
NCT00790894
|
Trial of Ixabepilone in Patients With HER-2 Negative Metastatic Breast Cancer (HIT)
|
https://clinicaltrials.gov/study/NCT00790894
|
TERMINATED
|
Metastatic Breast Cancer
|
DRUG: ixabepilone|DRUG: ixabepilone
|
Hellenic Cooperative Oncology Group
| null |
INTERVENTIONAL
|
NCT05134194
|
A Study of Camrelizumab in Combination With Chemotherapy Regimen Comparative Chemotherapy Regimen for Metastatic Triple-negative Breast Cancer
|
https://clinicaltrials.gov/study/NCT05134194
|
UNKNOWN
|
Triple Negative Breast Cancer
|
DRUG: Camrelizumab、Capecitabine/eribulin/gemcitabine/vinorelbine|DRUG: Capecitabine/eribulin/gemcitabine/vinorelbine
|
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
| null |
INTERVENTIONAL
|
NCT01222377
|
Endoscopic Breast Surgery in Treating Patients With Breast Cancer
|
https://clinicaltrials.gov/study/NCT01222377
|
TERMINATED
|
Male Breast Cancer|Recurrent Breast Cancer|Stage IA Breast Cancer|Stage IB Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer
|
PROCEDURE: endoscopic surgery|PROCEDURE: quality-of-life assessment
|
University of Southern California
|
National Cancer Institute (NCI)
|
INTERVENTIONAL
|
NCT02569294
|
Feasibility and Impact of Group Interventions on Breast Cancer Patients Well-being
|
https://clinicaltrials.gov/study/NCT02569294
|
COMPLETED
|
Breast Cancer
|
BEHAVIORAL: Yoga intervention|BEHAVIORAL: Hypnosis intervention|BEHAVIORAL: CBT intervention
|
University of Liege
| null |
INTERVENTIONAL
|
NCT04147494
|
Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues
|
https://clinicaltrials.gov/study/NCT04147494
|
RECRUITING
|
Breast Carcinoma|Colon Carcinoma|Esophageal Carcinoma|Gastric Carcinoma|Head and Neck Carcinoma|Kidney Carcinoma|Lung Carcinoma|Ovarian Carcinoma|Pancreatic Carcinoma|Solid Neoplasm|Uterine Corpus Cancer
|
PROCEDURE: Computed Tomography|RADIATION: Gallium Ga 68 FAPi-46|RADIATION: Gallium Ga 68-labeled PSMA-11|PROCEDURE: Positron Emission Tomography|RADIATION: 18F-FDG
|
Jonsson Comprehensive Cancer Center
|
Society of Nuclear Medecine and Molecular Imaging
|
INTERVENTIONAL
|
NCT03328494
|
Study of Paclitaxel in Combination With BOS172722 in Patients With Advanced Nonhaematologic Malignancies
|
https://clinicaltrials.gov/study/NCT03328494
|
COMPLETED
|
Advanced Nonhaematologic Malignancies
|
DRUG: BOS172722|DRUG: Paclitaxel
|
Boston Pharmaceuticals
| null |
INTERVENTIONAL
|
NCT02991677
|
Exercise Effect on Chemotherapy-Induced Neuropathic Pain
|
https://clinicaltrials.gov/study/NCT02991677
|
UNKNOWN
|
Cancer, Breast|Cancer, Colorectal|Cancer, Lung|Cancer, Ovarian
|
BEHAVIORAL: aerobic exercise intervention|OTHER: control group|BEHAVIORAL: resistive training
|
Baltimore VA Medical Center
| null |
INTERVENTIONAL
|
NCT01275677
|
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
|
https://clinicaltrials.gov/study/NCT01275677
|
ACTIVE_NOT_RECRUITING
|
HER2/Neu Positive|Progesterone Receptor Positive|Recurrent Breast Carcinoma|Stage IA Breast Cancer AJCC v7|Stage IB Breast Cancer AJCC v7|Stage IIA Breast Cancer AJCC v6 and v7|Stage IIB Breast Cancer AJCC v6 and v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7
|
DRUG: Cyclophosphamide|DRUG: Docetaxel|DRUG: Doxorubicin|DRUG: Doxorubicin Hydrochloride|OTHER: Laboratory Biomarker Analysis|DRUG: Paclitaxel|OTHER: Quality-of-Life Assessment|BIOLOGICAL: Trastuzumab
|
National Cancer Institute (NCI)
|
NRG Oncology
|
INTERVENTIONAL
|
NCT05968677
|
Effect of an Amino Acids and Flavonoids Containing FSMP on Chemotherapy Toxicity, Nutritional Status and Quality of Life in Breast Cancer Patients
|
https://clinicaltrials.gov/study/NCT05968677
|
RECRUITING
|
Breast Cancer
|
DIETARY_SUPPLEMENT: FSMP|OTHER: Nutritional counseling
|
Flavolife Srl
| null |
INTERVENTIONAL
|
NCT05291494
|
A Study on the Effectiveness of WeChat-based Online Education to Reduce Perioperative Anxiety in Breast Cancer Patients
|
https://clinicaltrials.gov/study/NCT05291494
|
COMPLETED
|
Breast Cancer Female
|
BEHAVIORAL: follow the WeChat public platform to watch the education videos|BEHAVIORAL: regular preoperative visits and education by ward nurses.
|
West China Hospital
| null |
INTERVENTIONAL
|
NCT04532177
|
Stereotactic Body Radiation Therapy (SBRT) for Invasive Breast Cancer Patients Not Undergoing Definitive Surgery
|
https://clinicaltrials.gov/study/NCT04532177
|
ACTIVE_NOT_RECRUITING
|
Breast Cancer
|
RADIATION: Stereotactic Body Radiation Therapy (SBRT)
|
Stony Brook University
| null |
INTERVENTIONAL
|
NCT03106077
|
Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer
|
https://clinicaltrials.gov/study/NCT03106077
|
COMPLETED
|
Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Estrogen Receptor Negative|Folate Receptor Alpha Positive|HER2/Neu Negative|Progesterone Receptor Negative|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8|Triple-Negative Breast Carcinoma
|
BIOLOGICAL: Mirvetuximab Soravtansine
|
M.D. Anderson Cancer Center
|
National Cancer Institute (NCI)
|
INTERVENTIONAL
|
NCT03888677
|
Dose-adjusted Adjuvant FEC Compared to Standard FEC for Breast Cancer
|
https://clinicaltrials.gov/study/NCT03888677
|
COMPLETED
|
Breast Cancer
|
DRUG: 5-FU, epirubicin and cyclophosphamide
|
Henrik Lindman
|
Scandinavian Breast Group|Danish Breast Cancer Cooperative Group|Swedish Cancer Society|Swedish Cancer Foundation|Pharmacia Pharmaceutical Company|Swedish Breast Cancer Group
|
INTERVENTIONAL
|
NCT05288777
|
Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer
|
https://clinicaltrials.gov/study/NCT05288777
|
RECRUITING
|
Breast Cancer|Breast Cancer Stage I|Breast Cancer Stage II|Breast Cancer Stage III
|
DRUG: T-DM1|DRUG: Capecitabine|RADIATION: External Beam Radiation Therapy 0|RADIATION: External Beam Radiation Therapy 1
|
University of Virginia
| null |
INTERVENTIONAL
|
NCT02521077
|
Intravenous Ascorbic Acid in Women Receiving Adjuvant or Neo-Adjuvant Chemotherapy for Early Stage Breast Cancer
|
https://clinicaltrials.gov/study/NCT02521077
|
WITHDRAWN
|
Fatigue
|
DRUG: Ascorbic Acid|OTHER: Normal Saline
|
Midwestern Regional Medical Center
| null |
INTERVENTIONAL
|
NCT03789877
|
A Home-Based Walking Program and rTMS in Helping Breast Cancer Survivors Get More Physical Activity
|
https://clinicaltrials.gov/study/NCT03789877
|
COMPLETED
|
Cancer Survivor|Invasive Breast Carcinoma
|
OTHER: Physical Activity|OTHER: Questionnaire Administration|PROCEDURE: Repetitive Transcranial Magnetic Stimulation|PROCEDURE: Sham Intervention
|
Roswell Park Cancer Institute
| null |
INTERVENTIONAL
|
NCT01980277
|
Phase Ib/II Study of LY2780301 in Combination With Weekly PACLITAXEL in HER2-metastatic Breast Cancer
|
https://clinicaltrials.gov/study/NCT01980277
|
TERMINATED
|
Breast Cancer
|
DRUG: LY2780301 + paclitaxel
|
Institut Paoli-Calmettes
| null |
INTERVENTIONAL
|
NCT05587777
|
Monitoring of Chronic Conditions in Breast Cancer
|
https://clinicaltrials.gov/study/NCT05587777
|
RECRUITING
|
Breast Cancer|Chronic Fatigue Syndrome
| null |
Helse Stavanger HF
| null |
OBSERVATIONAL
|
NCT04767594
|
First-line Palbociclib and Endocrine Therapy for Patients With HR+/HER2- Advanced Breast Cancer in the Real-world Setting.
|
https://clinicaltrials.gov/study/NCT04767594
|
RECRUITING
|
Breast Neoplasms
|
DRUG: Palbociclib + endocrine therapy
|
Pfizer
| null |
OBSERVATIONAL
|
NCT00148694
|
Preoperative Cisplatin in Early Stage Breast Cancer
|
https://clinicaltrials.gov/study/NCT00148694
|
COMPLETED
|
Breast Cancer
|
DRUG: Cisplatin
|
Dana-Farber Cancer Institute
|
Beth Israel Deaconess Medical Center|Massachusetts General Hospital|Brigham and Women's Hospital|Breast Cancer Research Foundation
|
INTERVENTIONAL
|
NCT03043794
|
Study of Stereotactic Radiotherapy for Breast Cancer
|
https://clinicaltrials.gov/study/NCT03043794
|
RECRUITING
|
Breast Cancer
|
RADIATION: Stereotactic Body Radiation SBRT
|
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
| null |
INTERVENTIONAL
|
NCT03321929
|
Intraoperative Detection of Residual Cancer in Breast Cancer
|
https://clinicaltrials.gov/study/NCT03321929
|
COMPLETED
|
Breast Cancer
|
COMBINATION_PRODUCT: LUM Imaging System
|
Lumicell, Inc.
|
National Cancer Institute (NCI)
|
INTERVENTIONAL
|
NCT04953377
|
PFMT Educational Intervention for Patients With Advancer Breast Cancer
|
https://clinicaltrials.gov/study/NCT04953377
|
RECRUITING
|
Advanced Breast Cancer
|
BEHAVIORAL: PFMT educational intervention
|
Onkologikoa
| null |
INTERVENTIONAL
|
NCT01594177
|
Dual Blockage With Afatinib and Trastuzumab as Neoadjuvant Treatment for Patients With Locally Advanced or Operable Breast Cancer Receiving Taxane-anthracycline Containing Chemotherapy
|
https://clinicaltrials.gov/study/NCT01594177
|
COMPLETED
|
Unilateral HER2 Positive Breast Cancer
|
DRUG: Afatinib|DRUG: Trastuzumab|DRUG: Paclitaxel|DRUG: Epirubicin|DRUG: Cyclophosphamide
|
German Breast Group
|
Boehringer Ingelheim
|
INTERVENTIONAL
|
NCT01625429
|
Neoadjuvant Study of Nab-paclitaxel Plus Carboplatin in Breast Cancer
|
https://clinicaltrials.gov/study/NCT01625429
|
UNKNOWN
|
Breast Cancer
|
DRUG: nab-paclitaxel
|
Shanghai Cancer Hospital, China
| null |
INTERVENTIONAL
|
NCT05928429
|
Effects of Cryotherapy on Taxane-Induced Neuropathy in Patients With Breast Cancer
|
https://clinicaltrials.gov/study/NCT05928429
|
RECRUITING
|
CIPN - Chemotherapy-Induced Peripheral Neuropathy|Breast Cancer
|
DEVICE: Elasto-Gel™ mitts for hands: TM7008, and slippers for feet: SL3000; Southwest Technologies, Inc., North Kansas City, MO, USA
|
Maria Lendorf
|
Danish Cancer Society|Aarhus University Hospital|Nordsjællands Hospital, Denmark|Hospital of Southern Jutland
|
INTERVENTIONAL
|
NCT00333229
|
A Study of Zoledronic Acid in the Prevention of Cancer Therapy-induced Bone Loss
|
https://clinicaltrials.gov/study/NCT00333229
|
TERMINATED
|
Primary Hormone Receptor Negative Breast Cancer in Premenopausal Women
|
DRUG: Zoledronic Acid|DRUG: Placebo
|
Novartis Pharmaceuticals
| null |
INTERVENTIONAL
|
NCT04755829
|
Breath Test to Predict Breast Cancer and Outcome of Mammography
|
https://clinicaltrials.gov/study/NCT04755829
|
UNKNOWN
|
Breast Cancer|Abnormal Mammogram, Unspecified
|
DEVICE: BreathX test for breath VOCs
|
Menssana Research, Inc.
|
Mount Vernon Cancer Centre|Zuyderland Medical Centre|University of Erlangen-Nürnberg
|
OBSERVATIONAL
|
NCT01978977
|
Maintenance Bevacizumab or Observation After Taxane Based First Line Chemotherapy In Metastatic Breast Cancer
|
https://clinicaltrials.gov/study/NCT01978977
|
COMPLETED
|
Metastatic Breast Cancer
| null |
Hellenic Oncology Research Group
| null |
OBSERVATIONAL
|
NCT05275777
|
A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer
|
https://clinicaltrials.gov/study/NCT05275777
|
RECRUITING
|
HER2-negative Breast Cancer|Advanced Solid Tumor
|
DRUG: ADG106|DRUG: Doxorubicin|DRUG: Cyclophosphamide|DRUG: Paclitaxel
|
National University Hospital, Singapore
|
Adagene Inc
|
INTERVENTIONAL
|
NCT05257577
|
Factors Influencing Breast Cancer Resection Volumes And Their Impact on Treatment Outcome (FIBRATIO)
|
https://clinicaltrials.gov/study/NCT05257577
|
ENROLLING_BY_INVITATION
|
Breast Cancer|Quality of Life|Patient Satisfaction|Resection Margin|Surgical Margin|Multidisciplinary Communication
|
PROCEDURE: Breast conserving surgery
|
Tampere University Hospital
|
Jyväskylä Central Hospital|Turku University Hospital|Kuopio University Hospital|North Karelia Central Hospital
|
OBSERVATIONAL
|
NCT00849329
|
A Study to Examine the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Lapatinib in Subjects With Metastatic ErbB2 Positive Breast Cancer
|
https://clinicaltrials.gov/study/NCT00849329
|
COMPLETED
|
Neoplasms, Breast
|
DRUG: lapatinib|DRUG: lapatinib plus esomeprazole
|
GlaxoSmithKline
| null |
INTERVENTIONAL
|
NCT04881929
|
Study of KN026 in Combination With Docetaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
https://clinicaltrials.gov/study/NCT04881929
|
RECRUITING
|
Breast Cancer
|
DRUG: KN026
|
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
| null |
INTERVENTIONAL
|
NCT04341129
|
Abbreviated MRI Protocol: Initial Experience With Dotarem® (Gadoterate Meglumine)
|
https://clinicaltrials.gov/study/NCT04341129
|
COMPLETED
|
Breast Neoplasms|Breast Diseases|Breast Fibroadenoma|Breast Cancer
|
DRUG: Abbreviated MRI protocol: initial experience with Dotarem® (Gadoterate Meglumine)
|
University of Chicago
|
Guerbet
|
INTERVENTIONAL
|
NCT00662129
|
Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Gemcitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer
|
https://clinicaltrials.gov/study/NCT00662129
|
COMPLETED
|
Breast Cancer
|
BIOLOGICAL: bevacizumab|DRUG: gemcitabine hydrochloride|DRUG: paclitaxel albumin-stabilized nanoparticle formulation
|
Alliance for Clinical Trials in Oncology
|
National Cancer Institute (NCI)
|
INTERVENTIONAL
|
NCT04012229
|
IMpact of Breast cAncer Gene Status on Survival in Adjuvant Breast Cancer (IMBASSA)
|
https://clinicaltrials.gov/study/NCT04012229
|
COMPLETED
|
Breast Cancer|BRCA1 Mutation|BRCA2 Mutation
|
GENETIC: BRCA mutation
|
Centre Hospitalier Universitaire de Besancon
| null |
OBSERVATIONAL
|
NCT02041429
|
Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca
|
https://clinicaltrials.gov/study/NCT02041429
|
COMPLETED
|
Recurrent Breast Cancer|Metastatic Breast Cancer
|
DRUG: Ruxolitinib|DRUG: Paclitaxel
|
Dana-Farber Cancer Institute
|
Incyte Corporation
|
INTERVENTIONAL
|
NCT00385177
|
Phase 1 Dose Escalation Study of SN2310 Injectable Emulsion in Patients With Advanced Solid Tumors
|
https://clinicaltrials.gov/study/NCT00385177
|
COMPLETED
|
Breast Neoplasms|Colorectal Neoplasms|Pancreatic Neoplasms|Pelvic Neoplasms|Lung Neoplasms
|
DRUG: SN2310 Injectable Emulsion
|
Achieve Life Sciences
| null |
INTERVENTIONAL
|
NCT05564377
|
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
|
https://clinicaltrials.gov/study/NCT05564377
|
RECRUITING
|
Advanced Malignant Solid Neoplasm|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Locally Advanced Malignant Solid Neoplasm|Malignant Female Reproductive System Neoplasm|Metastatic HER2-Negative Breast Carcinoma|Metastatic Malignant Solid Neoplasm|Recurrent Endometrial Carcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Malignant Female Reproductive System Neoplasm|Recurrent Malignant Solid Neoplasm|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Unresectable HER2-Negative Breast Carcinoma|Unresectable Malignant Solid Neoplasm
|
DRUG: Alpelisib|DRUG: Binimetinib|PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|PROCEDURE: Bone Marrow Aspiration|PROCEDURE: Bone Scan|PROCEDURE: Computed Tomography|PROCEDURE: Echocardiography|DRUG: Fluorouracil|DRUG: Fulvestrant|DRUG: Ipatasertib|DRUG: Leucovorin|PROCEDURE: Magnetic Resonance Imaging|PROCEDURE: Multigated Acquisition Scan|PROCEDURE: Mutation Carrier Screening|DRUG: Neratinib Maleate|DRUG: Nilotinib Hydrochloride Monohydrate|DRUG: Olaparib|DRUG: Oxaliplatin|DRUG: Paclitaxel|DRUG: Palbociclib|BIOLOGICAL: Panitumumab|PROCEDURE: Positron Emission Tomography|DRUG: Selumetinib Sulfate|DRUG: Sotorasib
|
National Cancer Institute (NCI)
| null |
INTERVENTIONAL
|
NCT04689529
|
Unnecessary Mastectomy Due to False Size Prediction by Preoperative Imaging Studies in Breast Cancer
|
https://clinicaltrials.gov/study/NCT04689529
|
ACTIVE_NOT_RECRUITING
|
Breast Cancer|Surgery|IMAGE|Chemotherapy Effect
|
DIAGNOSTIC_TEST: Preoperative imaging study
|
Seoul National University Hospital
| null |
INTERVENTIONAL
|
NCT00003877
|
Peripheral Stem Cell Transplantation With or Without Stromagen Following Chemotherapy in Treating Women With Metastatic Breast Cancer
|
https://clinicaltrials.gov/study/NCT00003877
|
COMPLETED
|
Breast Cancer
|
BIOLOGICAL: filgrastim|DRUG: carboplatin|DRUG: cyclophosphamide|DRUG: paclitaxel|DRUG: thiotepa|PROCEDURE: in vitro-treated bone marrow transplantation|PROCEDURE: in vitro-treated peripheral blood stem cell transplantation
|
Roswell Park Cancer Institute
|
National Cancer Institute (NCI)
|
INTERVENTIONAL
|
NCT01649271
|
Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.
|
https://clinicaltrials.gov/study/NCT01649271
|
COMPLETED
|
Breast Neoplasms|Stomach Neoplasms
|
DRUG: Herceptin|DRUG: afatinib|DRUG: trastuzumab|DRUG: Herceptin|DRUG: afatinib|DRUG: afatinib
|
Boehringer Ingelheim
| null |
INTERVENTIONAL
|
NCT01702571
|
A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment
|
https://clinicaltrials.gov/study/NCT01702571
|
COMPLETED
|
Breast Cancer
|
DRUG: Trastuzumab Emtansine
|
Hoffmann-La Roche
| null |
INTERVENTIONAL
|
NCT01120171
|
Myocet Plus Endoxan for Older Patients With Breast Cancer
|
https://clinicaltrials.gov/study/NCT01120171
|
TERMINATED
|
Breast Cancer
|
DRUG: Cyclophosphamide|DRUG: Liposomal-encapsulated doxorubicin
|
Hellenic Oncology Research Group
| null |
INTERVENTIONAL
|
NCT03939871
|
A Study of Fluvestrant Combined With Oral Vinorelbine in Hormone Receptor-positive Advanced Breast Cancer
|
https://clinicaltrials.gov/study/NCT03939871
|
UNKNOWN
|
Hormone Receptor Positive Advanced Breast Cancer
|
DRUG: fluvestrant + oral vinorelbine
|
Chinese Academy of Medical Sciences
| null |
INTERVENTIONAL
|
NCT05894239
|
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
|
https://clinicaltrials.gov/study/NCT05894239
|
RECRUITING
|
Metastatic Breast Cancer
|
DRUG: Inavolisib|DRUG: Phesgo|DRUG: Placebo|DRUG: Taxane-based Chemotherapy|DRUG: Optional Endocrine Therapy of Investigator's Choice
|
Hoffmann-La Roche
| null |
INTERVENTIONAL
|
NCT00393939
|
Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast Cancer
|
https://clinicaltrials.gov/study/NCT00393939
|
COMPLETED
|
Breast Neoplasms
|
DRUG: Sunitinib malate|DRUG: Taxotere
|
Pfizer
| null |
INTERVENTIONAL
|
NCT00967239
|
Study of Blood Samples From High-Risk Postmenopausal Women Who Received Treatment on Breast Cancer Prevention Clinical Trials NSABP-P-1 or NSABP-P-2
|
https://clinicaltrials.gov/study/NCT00967239
|
UNKNOWN
|
Breast Cancer
|
GENETIC: DNA analysis|GENETIC: polymorphism analysis|OTHER: laboratory biomarker analysis|OTHER: pharmacogenomic studies
|
NSABP Foundation Inc
|
National Cancer Institute (NCI)
|
OBSERVATIONAL
|
NCT01367639
|
Trial of Inquiry Based Stress Reduction (IBSR) Program for BRCA1/2 Mutation Carriers
|
https://clinicaltrials.gov/study/NCT01367639
|
COMPLETED
|
Hereditary Breast and Ovarian Cancer Syndrome
|
BEHAVIORAL: Inquiry Based Stress Reduction (IBSR) program
|
Sheba Medical Center
| null |
INTERVENTIONAL
|
NCT03265379
|
Improving Quality of Life for Patients With Breast Cancer Invading the Chest Wall: A Prospective Registry For Patients Undergoing Full Thickness Chest Wall Resection
|
https://clinicaltrials.gov/study/NCT03265379
|
RECRUITING
|
Breast Cancer
|
OTHER: FACT-B and Brief Pain Inventory
|
University Health Network, Toronto
| null |
OBSERVATIONAL
|
NCT04028479
|
The Registry of Oncology Outcomes Associated With Testing and Treatment
|
https://clinicaltrials.gov/study/NCT04028479
|
RECRUITING
|
Adenocarcinoma|Adenocystic Carcinoma|Anal Cancer|Appendix Cancer|Brain Tumor|Glioblastoma|Astrocytoma|Bile Duct Cancer|Cholangiocarcinoma|Bladder Cancer|Bone Cancer|Synovial Sarcoma|Chondrosarcoma|Liposarcoma|Sarcoma, Kaposi|Sarcoma,Soft Tissue|Sarcoma|Osteosarcoma|CNS Cancer|Brain Stem Neoplasms|Breast Cancer|Cervical Cancer|Colorectal Cancer|Rectal Cancer|Colon Cancer|Esophageal Cancer|Esophagus Cancer|Cancer of Colon|Pancreatic Cancer|Cancer of Pancreas|Testis Cancer|Testicular Cancer|Ureter Cancer|Renal Cell Carcinoma|Kidney Cancer|Gestational Trophoblastic Tumor|Head and Neck Neoplasms|Parotid Tumor|Larynx Cancer|Tongue Cancer|Pharynx Cancer|Salivary Gland Cancer|Acute Myeloid Leukemia|Chronic Myeloid Leukemia|Acute Lymphoblastic Leukemia|Multiple Myeloma|Non Hodgkin Lymphoma|Carcinoid Tumor|Lung Cancer|Neuroendocrine Tumors|Mesothelioma|Thyroid Cancer|Parathyroid Neoplasms|Adrenal Cancer|Small Bowel Cancer|Stomach Cancer|Liver Cancer|Hepatic Cancer|Melanoma|Skin Cancer|Unknown Primary Tumors|Uterine Cancer|Fallopian Tube Cancer|Ovarian Cancer|Prostate Cancer|Vaginal Cancer|Penile Cancer|Vulvar Cancer|Waldenstrom Macroglobulinemia|Cancer, Advanced|Thymus Cancer|Nasopharyngeal Carcinoma|Multiple Endocrine Neoplasia|Pheochromocytoma|Small Cell Carcinoma|Pulmonary Carcinoma
|
DIAGNOSTIC_TEST: Biomarker Testing (L)|DRUG: Systemic Treatment (T)|OTHER: Patient Reported Outcomes (P)
|
Taproot Health
| null |
OBSERVATIONAL
|
NCT00419679
|
Use of Hair to Diagnose Breast Cancer
|
https://clinicaltrials.gov/study/NCT00419679
|
UNKNOWN
|
Breast Neoplasms
|
PROCEDURE: x-ray diffraction of human hair
|
Fermiscan Ltd
| null |
INTERVENTIONAL
|
NCT03176979
|
Contrast Enhanced Spectral Mammography With Digital Breast Tomosynthesis For Patients With Newly Diagnosed Breast Cancer
|
https://clinicaltrials.gov/study/NCT03176979
|
COMPLETED
|
Breast Carcinoma
|
OTHER: Contrast Agent|PROCEDURE: Digital Tomosynthesis Mammography|PROCEDURE: Dual-Energy Contrast-Enhanced Digital Spectral Mammography
|
University of Southern California
|
National Cancer Institute (NCI)
|
INTERVENTIONAL
|
NCT05739591
|
Long-term Safety and Efficacy of GBG Study Participants
|
https://clinicaltrials.gov/study/NCT05739591
|
RECRUITING
|
Breast Cancer
| null |
German Breast Group
| null |
OBSERVATIONAL
|
NCT02902991
|
The Study on the Clinical Utility of Liquid Biopsy in Breast Cancer
|
https://clinicaltrials.gov/study/NCT02902991
|
UNKNOWN
|
Breast Cancer
| null |
Peking Union Medical College
| null |
OBSERVATIONAL
|
NCT01254591
|
Positron Emission Tomography/Computed Tomography Scanning Before Surgery in Patients With Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Esophageal Cancer, or Head and Neck Cancer
|
https://clinicaltrials.gov/study/NCT01254591
|
UNKNOWN
|
Breast Cancer|Colorectal Cancer|Esophageal Cancer|Head and Neck Cancer|Lung Cancer
|
OTHER: 18F-fluoromisonidazole|OTHER: fluorescence angiography|OTHER: laboratory biomarker analysis|PROCEDURE: infrared thermography|PROCEDURE: magnetic resonance imaging|PROCEDURE: therapeutic conventional surgery|RADIATION: [18F]-ML-10|RADIATION: fludeoxyglucose F 18|RADIATION: rubidium Rb-82
|
University College London (UCL) Cancer Institute
| null |
INTERVENTIONAL
|
NCT00046891
|
EGb761 in Maintaining Mental Clarity in Women Receiving Chemotherapy for Newly Diagnosed Breast Cancer
|
https://clinicaltrials.gov/study/NCT00046891
|
COMPLETED
|
Breast Cancer|Neurotoxicity
|
DRUG: Ginkgo Biloba|OTHER: Placebo
|
Alliance for Clinical Trials in Oncology
|
National Cancer Institute (NCI)
|
INTERVENTIONAL
|
NCT05986071
|
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers
|
https://clinicaltrials.gov/study/NCT05986071
|
NOT_YET_RECRUITING
|
Breast Cancer
|
DRUG: M1774|DRUG: Fulvestrant injection
|
Institut Paoli-Calmettes
|
Merck Sharp & Dohme LLC|National Cancer Institute, France
|
INTERVENTIONAL
|
NCT02248571
|
Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab
|
https://clinicaltrials.gov/study/NCT02248571
|
COMPLETED
|
Breast Cancer Recurrent|HER2/Neu-negative Carcinoma of Breast|Hormone Receptor Positive Malignant Neoplasm of Breast
|
DRUG: Bevacizumab|DRUG: Capecitabine|DRUG: Everolimus|DRUG: Exemestane|OTHER: Patient questionaires
|
iOMEDICO AG
|
Arbeitsgemeinschaft fur Internistische Onkologie|Novartis Pharmaceuticals
|
INTERVENTIONAL
|
NCT04496739
|
Making Informed Choices on Incorporating Chemoprevention Into Care (MiCHOICE)
|
https://clinicaltrials.gov/study/NCT04496739
|
RECRUITING
|
Atypical Hyperplasia of the Breast|Lobular Breast Carcinoma In Situ|Pleomorphic Lobular Breast Carcinoma In Situ
|
BEHAVIORAL: Cancer Educational Materials|OTHER: Decision Aid|OTHER: Decision Aid|OTHER: Interview|OTHER: Questionnaire Administration
|
SWOG Cancer Research Network
|
National Cancer Institute (NCI)
|
INTERVENTIONAL
|
NCT03257839
|
Delphinus SoftVue Prospective Case Collection - ARM 1
|
https://clinicaltrials.gov/study/NCT03257839
|
COMPLETED
|
Breast Neoplasms
|
DEVICE: Routine Full-Field Digital Mammography|DEVICE: Routine Digital Breast Tomosynthesis|DEVICE: Automated Whole Breast Ultrasound
|
Delphinus Medical Technologies, Inc.
| null |
OBSERVATIONAL
|
NCT05720039
|
Robotic vs. Open NSM for Early Stage Breast Cancer
|
https://clinicaltrials.gov/study/NCT05720039
|
RECRUITING
|
Breast Cancer Female|Breast Cancer|Breast Cancer, Early-Onset|Breast Disease|Breast
|
DEVICE: Robotic NSM|PROCEDURE: Open NSM
|
Intuitive Surgical
| null |
INTERVENTIONAL
|
NCT00074139
|
Docetaxel, Doxorubicin, and Cyclophosphamide in Treating Women With Advanced Breast Cancer
|
https://clinicaltrials.gov/study/NCT00074139
|
WITHDRAWN
|
Breast Cancer
|
DRUG: cyclophosphamide|DRUG: docetaxel|DRUG: doxorubicin hydrochloride
|
Case Comprehensive Cancer Center
|
National Cancer Institute (NCI)
|
INTERVENTIONAL
|
NCT04657679
|
Pharmacokinetics and Pharmacogenomics of Ribociclib in Race-based Cohorts
|
https://clinicaltrials.gov/study/NCT04657679
|
TERMINATED
|
Breast Cancer
|
DRUG: Ribociclib
|
Georgetown University
|
Medstar Health Research Institute|Breast Cancer Research Foundation|Georgetown-Howard Universities Center for Clinical and Translational Science (GHUCCTS)
|
INTERVENTIONAL
|
NCT00496379
|
ZK219477 (Sagopilone) in Patients With Breast Cancer and Brain Metastases
|
https://clinicaltrials.gov/study/NCT00496379
|
TERMINATED
|
Breast Cancer|CNS Disease
|
DRUG: ZK219477
|
Nancy Lin, MD
|
Brigham and Women's Hospital|Bayer|Breast Cancer Research Foundation
|
INTERVENTIONAL
|
NCT05633979
|
Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer
|
https://clinicaltrials.gov/study/NCT05633979
|
RECRUITING
|
Breast Cancer
|
DRUG: Trastuzumab deruxtecan|DRUG: Valemetostat
|
M.D. Anderson Cancer Center
|
Daiichi Sankyo
|
INTERVENTIONAL
|
NCT01463891
|
Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer (Study HAL01S)
|
https://clinicaltrials.gov/study/NCT01463891
|
COMPLETED
|
Inoperable or Recurrent Breast Cancer
|
DRUG: Eribulin Mesylate
|
Eisai Co., Ltd.
| null |
OBSERVATIONAL
|
NCT00161291
|
Open Label Trial for Post-Menopausal Women With Newly Diagnosed Operable Breast Cancer
|
https://clinicaltrials.gov/study/NCT00161291
|
COMPLETED
|
Breast Cancer
|
DRUG: Letrozole in combination with Bevacizumab
|
University of Alabama at Birmingham
|
Genentech, Inc.
|
INTERVENTIONAL
|
NCT05365191
|
A Study Evaluating Near-infrared Zone II Imaging in Sentinel Lymph Node Mapping in Breast Cancer Patients
|
https://clinicaltrials.gov/study/NCT05365191
|
RECRUITING
|
Breast Cancer|Sentinel Lymph Node
|
PROCEDURE: Near infrared fluorescence navigated sentinel lymph node mapping
|
National Taiwan University Hospital Hsin-Chu Branch
|
National Yang Ming Chiao Tung University
|
INTERVENTIONAL
|
NCT01846091
|
Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer
|
https://clinicaltrials.gov/study/NCT01846091
|
COMPLETED
|
Estrogen Receptor Negative|Estrogen Receptor Positive|Head and Neck Squamous Cell Carcinoma|HER2/Neu Negative|HER2/Neu Positive|Invasive Breast Carcinoma|Progesterone Receptor Negative|Progesterone Receptor Positive|Recurrent Head and Neck Carcinoma|Stage IV Breast Cancer|Triple-Negative Breast Carcinoma
|
OTHER: Laboratory Biomarker Analysis|BIOLOGICAL: Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
|
Mayo Clinic
|
National Cancer Institute (NCI)
|
INTERVENTIONAL
|
NCT03564171
|
Prehabilitation for Women Undergoing Pre-operative Chemotherapy for Breast Cancer
|
https://clinicaltrials.gov/study/NCT03564171
|
COMPLETED
|
Breast Cancer|Rehabilitation|Neoadjuvant Therapy|Feasibility Studies
|
COMBINATION_PRODUCT: Prehabilitation
|
Sunnybrook Health Sciences Centre
|
University Health Network, Toronto
|
INTERVENTIONAL
|
NCT02780271
|
Diet and Physical Activity Changes Among Latina Breast Cancer Survivors
|
https://clinicaltrials.gov/study/NCT02780271
|
COMPLETED
|
Breast Cancer
|
BEHAVIORAL: In-person education|BEHAVIORAL: E-communication|BEHAVIORAL: Control
|
Columbia University
|
National Cancer Institute (NCI)
|
INTERVENTIONAL
|
NCT02620371
|
Efficacy of Ketamine Added to Local Anesthetic in Modified Pectoral Block for Management of Postoperative Pain
|
https://clinicaltrials.gov/study/NCT02620371
|
COMPLETED
|
Breast Cancer
|
PROCEDURE: modified pectoral block
|
Assiut University
| null |
INTERVENTIONAL
|
NCT00246571
|
Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer
|
https://clinicaltrials.gov/study/NCT00246571
|
COMPLETED
|
Breast Neoplasms
|
DRUG: SU011248|DRUG: Chemotherapy
|
Pfizer
| null |
INTERVENTIONAL
|
NCT05891171
|
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
|
https://clinicaltrials.gov/study/NCT05891171
|
RECRUITING
|
Advanced Cancer|Advanced Malignancies|Bladder Cancer|Cervical Cancer|Esophageal Cancer|Gastric Cancer|Gastroesophageal-junction Cancer (GEJ)|Head and Neck Squamous Cell Carcinoma (HNSCC)|Non-Small Cell Lung Cancer (NSCLC)|Ovarian Cancer|Renal Cell Carcinoma (RCC)|Triple Negative Breast Cancer (TNBC)
|
DRUG: AB598|DRUG: Zimberelimab|DRUG: Carboplatin|DRUG: Pemetrexed|DRUG: Fluorouracil|DRUG: Leucovorin|DRUG: Oxaliplatin
|
Arcus Biosciences, Inc.
| null |
INTERVENTIONAL
|
NCT04175639
|
mHealth Behavioral Cancer Pain Intervention for Medically Undeserved Patients
|
https://clinicaltrials.gov/study/NCT04175639
|
RECRUITING
|
Breast Cancer
|
BEHAVIORAL: Mobile Health Pain Coping Skills Training (mPCST)
|
Duke University
| null |
INTERVENTIONAL
|
NCT01313039
|
Evaluation of the Use of AZD6244 to Induce Increased ER Expression and Anti-Estrogen Response in ER-Negative/Low Breast Cancer
|
https://clinicaltrials.gov/study/NCT01313039
|
COMPLETED
|
Breast Cancer
|
DRUG: AZ6244
|
University of Miami
| null |
INTERVENTIONAL
|
NCT00976339
|
Study of Vitamin D for Premenopausal Women at High Risk for Breast Cancer
|
https://clinicaltrials.gov/study/NCT00976339
|
COMPLETED
|
Breast Cancer
|
DRUG: Cholecalciferol
|
Katherine D. Crew
|
Prevent Cancer Foundation
|
INTERVENTIONAL
|
NCT05287139
|
QOL of Women With HR-Positive Metastatic BC Treated in the First-line Setting: Comparison Between Public and Private Institutions.
|
https://clinicaltrials.gov/study/NCT05287139
|
ENROLLING_BY_INVITATION
|
Quality of Life|Breast Neoplasm Female
|
OTHER: Quality of Life
|
Beneficência Portuguesa de São Paulo
| null |
OBSERVATIONAL
|
NCT03579979
|
Sentinel Lymph Node Biopsy in Breast Cancer Surgery Using ICG
|
https://clinicaltrials.gov/study/NCT03579979
|
COMPLETED
|
Sentinel Lymph Node|Breast Cancer
|
DRUG: Methylene Blue|DRUG: Indocyanine Green
|
Chinese Academy of Sciences
|
Beijing Digital Precesion Medicine Company|Cancer Institute and Hospital, Chinese Academy of Medical Sciences|Beijing Friendship Hospital|Tangshan People's Hospital|The Second Hospital of Hebei Medical University
|
INTERVENTIONAL
|
NCT00952679
|
Computed Tomography (CT) Based Lymphatic Mapping and Localization of Sentinel Lymph Node in Breast Cancer Patients
|
https://clinicaltrials.gov/study/NCT00952679
|
UNKNOWN
|
Breast Cancer
|
DEVICE: Breast Lesion Localization Needles (interv)
|
Fudan University
| null |
INTERVENTIONAL
|
NCT02022579
|
DCE-MRI and DWI for Detection and Diagnosis of Breast Cancer
|
https://clinicaltrials.gov/study/NCT02022579
|
UNKNOWN
|
Breast Cancer|BIRADS 3|BIRADS 4|BIRADS 5
|
PROCEDURE: DCE-MRI and DWI
|
American College of Radiology Imaging Network
|
National Cancer Institute (NCI)|Eastern Cooperative Oncology Group
|
INTERVENTIONAL
|
NCT04166279
|
The Recovery of Reaching Movement in Breast Cancer Survivors: Two Different Rehabilitative Protocols in Comparison
|
https://clinicaltrials.gov/study/NCT04166279
|
COMPLETED
|
Breast Cancer|Breast Cancer Lymphedema|Pain|Pain, Postoperative|Pain, Chronic|Mastectomy; Lymphedema|Breast Surgery
|
OTHER: Single rehabilitative treatment|OTHER: Group rehabilitative treatment
|
University of Roma La Sapienza
| null |
INTERVENTIONAL
|
NCT01479179
|
Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on Trastuzumab
|
https://clinicaltrials.gov/study/NCT01479179
|
WITHDRAWN
|
Breast Cancer
|
DRUG: AMG 479|DRUG: Trastuzumab
|
M.D. Anderson Cancer Center
|
Amgen
|
INTERVENTIONAL
|
NCT05011279
|
Move Together Boston Feasibility Pilot (Sit Less, Move More App for Black Breast Cancer Survivors & At-Risk Relatives)
|
https://clinicaltrials.gov/study/NCT05011279
|
COMPLETED
|
Breast Cancer Survivor|Breast Cancer|Fitness Trackers
|
OTHER: Move Together app/Garmin Activity Tracker
|
Dana-Farber Cancer Institute
|
University of Massachusetts, Boston|University of Rochester|National Cancer Institute (NCI)
|
INTERVENTIONAL
|
NCT04683679
|
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
|
https://clinicaltrials.gov/study/NCT04683679
|
RECRUITING
|
Triple Negative Breast Cancer|TNBC - Triple-Negative Breast Cancer|Breast Cancer|Metastatic Breast Cancer
|
DRUG: Pembrolizumab|DRUG: Olaparib|RADIATION: Radiation
|
Memorial Sloan Kettering Cancer Center
| null |
INTERVENTIONAL
|
NCT04206891
|
CDH1 Germline Mutations in Lobular Breast Cancer
|
https://clinicaltrials.gov/study/NCT04206891
|
ACTIVE_NOT_RECRUITING
|
Lobular Breast Carcinoma|CDH1 Gene Inactivation
| null |
European Institute of Oncology
| null |
OBSERVATIONAL
|
NCT04583891
|
Mobile Apps to Reduce Distress in Breast Cancer Survivors Using an Adaptive Design
|
https://clinicaltrials.gov/study/NCT04583891
|
ACTIVE_NOT_RECRUITING
|
Depression, Anxiety|Engagement, Patient
|
BEHAVIORAL: IntelliCare|BEHAVIORAL: Psychoeducation|BEHAVIORAL: Coaching
|
University of Virginia
|
Northwestern University
|
INTERVENTIONAL
|
NCT05731791
|
Trial to Compare MRI-guided Precision Prone Irradiation (PPI) Versus CT-guided Breast Irradiation
|
https://clinicaltrials.gov/study/NCT05731791
|
RECRUITING
|
Breast Cancer
|
RADIATION: Radiation Therapy to partial breast
|
Weill Medical College of Cornell University
| null |
INTERVENTIONAL
|
NCT00014391
|
Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation
|
https://clinicaltrials.gov/study/NCT00014391
|
COMPLETED
|
Cancer
|
BIOLOGICAL: palivizumab|DRUG: ribavirin
|
Fred Hutchinson Cancer Center
|
National Cancer Institute (NCI)
|
INTERVENTIONAL
|
NCT05297591
|
Identifying Prognostic Variables for Persistent Upper Limb Dysfunctions After Breast Cancer Treatment
|
https://clinicaltrials.gov/study/NCT05297591
|
RECRUITING
|
Breast Cancer
|
OTHER: assessment of UL function and prognostic factors
|
KU Leuven
|
Universitaire Ziekenhuizen KU Leuven|Vrije Universiteit Brussel
|
INTERVENTIONAL
|
End of preview. Expand
in Data Studio
README.md exists but content is empty.
- Downloads last month
- 4